Table 5. Comparison between the molecular test results and fulfilment of clinical guidelines.
| MSI status | BRAF mutation | MLH1 meth | N=336 | RBG positive | RBG negative | AM II positive | AM II negative | |
|---|---|---|---|---|---|---|---|---|
| LS | MSI-H | Wt | Neg | 12 | 6 | 6 | 3 | 9 |
| Non-LS | MSI-H | Wt | Pos | 6 | 1 | 5 | 0 | 6 |
| MSI-H sporadic CRC likely | MSI-H | V600E | Pos | 39 | 11 | 28 | 0 | 39 |
| Non-LS | MSS | Wt | Neg | 260 | 63 | 197 | 5 | 255 |
| Non-LS (sporadic CRC likely) | MSS | V600E | Neg | 19 | 6 | 12 | 0 | 19 |
| Total | 336 | 87 | 249 | 8 | 328 |
Abbreviations: AM II neg=Amsterdam II criteria not fulfilled; AM II pos=Amsterdam II criteria fulfilled; CRC=colorectal cancer; LS=Lynch syndrome; MLH1 meth neg=absence of MLH1 methylation; MLH1 meth pos=methylation of MLH1; MSI=microsatellite instability; MSI-H=microsatellite instable tumour; MSS=microsatellite stable tumour; non-LS=CRC not associated with Lynch syndrome; RBG pos=Revised Bethesda Guidelines fulfilled; RBG neg=Revised Bethesda Guidelines not fulfilled; V600E=presence of the BRAF oncogene; Wt=absence of the BRAF oncogene.